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The microtubule-associated protein tau (MAPT) region has been conceptualized as
a model of the interaction between genetics and functional disease outcomes in
neurodegenerative disorders, such as Parkinson disease (PD). Indeed, haplotype-
specific differences in expression and alternative splicing of MAPT transcripts
affect cellular functions at different levels, increasing susceptibility to a range of
neurodegenerative processes. In order to evaluate a possible link between MAPT
variants, PD risk and PD motor phenotype, we analyzed the genetic architecture of
MAPT in a cohort of PD patients. We observed a statistically significant association
between the H1 haplotype and PD risk (79.5 vs 69.5%; 2χ = 9.9; OR, 1.7; 95% CI,
1.2–2.4; p = 0.002). The effect was more evident in non tremor dominant (TD) PD
subjects (NTD-PD) (82 vs 69.5%; 2χ = 13.6; OR, 2.03; 95% CI, 1.4–3; p = 0.0003),
while no difference emerged between PD subgroup of tremor dominant patients (TD-PD)
and control subjects. Examination of specific intra-H1 variations showed that the
H1h subhaplotype was overrepresented in NTD-PD patients compared with controls
(p = 0.007; OR, 2.9; 95% CI, 1.3–6.3). Although we cannot exclude that MAPT variation
may be associated with ethnicity, our results may support the hypothesis that MAPT H1
clade and a specific H1 subhaplotype influence the risk of PD and modulate the clinical
expression of the disease, including motor phenotype.
Keywords: microtubule-associated protein tau gene, h1 subhaplotype, Parkinson disease, non tremor dominant
Parkinson disease, tremor dominant Parkinson disease, Parkinson subtype
INTRODUCTION
The microtubule-associated protein tau (MAPT) is a phosphorylated protein primarily expressed
in the brain, where it assists in stabilization of the cytoskeleton and axonal transport in neurons.
The human gene encoding MAPT lies on chromosome 17q21, within a∼900 kb ancestral genomic
inversion that generates a ∼1.8 megabase (Mb) region of linkage disequilibrium (LD) defined
by two extended haplotypes, referred to as H1 and H2 (Baker et al., 1999). In contrast to H2,
the H1 haplotype is evolutionarily dynamic and contains a number of variation composed of
single nucleotide polymorphisms (SNP) highly correlated with each other (Pittman et al., 2005).
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Dominantly inherited mutations in MAPT were formerly
associated with forms of frontotemporal dementia and
parkinsonism linked to chromosome 17, first providing evidence
of a link between tau dysfunction and neurodegeneration
(Hutton et al., 1998; Spillantini et al., 1998). Beside dominantly
inherited diseases, the most common H1 haplotype has been
linked not only to tauopathies such as Alzheimer’s disease
(AD), progressive supranuclear palsy (PSP) and corticobasal
degeneration (CBD; Myers et al., 2005; Pittman et al., 2006) but
also to the most common synucleinopathy such as Parkinson
disease (PD), providing mostly positive albeit partially conflicting
results (see Zabetian et al., 2007 for summary). However, the
impact of H1 haplotype as a risk factor for PD has been
confirmed in GWAS studies (Simón-Sánchez et al., 2009;
Edwards et al., 2010) and meta-analysis by the PDGene forum1
(Lill et al., 2012).
Given the convergent data indicating a role of MAPT locus in
PD, recent lines of research have moved to refine the potential
effect of H1 haplotype into phenotypic traits of the malady
(Huang et al., 2015; Davis et al., 2016; Wang et al., 2016), such as
the progression of cognitive deficits (Williams-Gray et al., 2009;
Seto-Salvia et al., 2011) and motor clinical subtype (Di Battista
et al., 2014).
Moreover, taking into account that the true allele risk
associated with neurodegenerative disorders could reside at
any position within an approximately 900 kb region, that
includes genes other than MAPT, the H1 haplotype has been
partitioned into several H1-specific subhaplotypes in order to
more precisely map the disease-associated region. Currently fine-
mapping studies of the MAPT H1/H2 clades have identified
specific subhaplotypes associated with AD (Myers et al., 2005)
and PSP (Pittman et al., 2005), while mostly conflicting results
have been described with PD (Fung et al., 2006; Tobin et al., 2008;
Vandrovcova et al., 2009; Seto-Salvia et al., 2011).
Therefore, we sought to analyze the genetic architecture of
MAPT in a cohort of PD patients where we had formerly
observed an association between H1 homozygosity and non-
tremor dominant (NTD) PD subtype, and whether specific
variants of the H1 clade were linked with clinical phenotypes.
MATERIALS AND METHODS
Subjects
A total of 197 unrelated control subjects (mean age: 68.2 ±
18.8, 67% male) and 181 unrelated sporadic PD patients (mean
age: 70.9 ± 8.4 years, 56% male, mean age of diagnosis: 60.7
years) were consecutively recruited from March 2011 to July
2012 for the present study. This study cohort has been formerly
described in a published study (Di Battista et al., 2014) that
analyzed PD motor subtypes in H1 homozygote vs. H2 carriers,
no control subjects were enrolled for our previous report. All
patients were of European ancestry and originated from the
regions of Central and Southern Italy. Patients were selected
from the Parkinson outpatient center of the Sapienza University
of Rome and fulfilled the UK Brain Bank criteria for PD.
1http://www.pdgene.org/
Patients with signs of atypical parkinsonism, doubtful response
to dopaminergic replacement therapy, dementia (Mini-Mental
State Examination score< 24) or unreliable clinical data (disease
duration ≤ 3 years, less than three clinical assessments) were not
included.
Clinical Assessment
For the assignment of clinical subtype, the patients underwent
at least three clinical assessments by two expert neurologists in
movement disorders during the study period, moreover, clinical
notes were reviewed to obtain retrospective data on clinical onset.
The UPDRS III performed in the last visit is reported. The
patients were classified into two clinical subtypes, by applying
the criteria published in a previous study (Selikhova et al.,
2009): (a) tremor dominant (TD), i.e., patients with tremor
as the only motor sign at onset or tremor as the prominent
motor symptom according to the UPDRS part III; (b) NTD,
i.e., patients with predominant rigidity and bradykinesia but
no tremor or only mild tremor at rest. Only patients with
at least 3 years of disease duration were enrolled for the
study in order to obtain a reasonable depiction of the clinical
subtype.
Clinicians were blinded of patients MAPT background during
the study examinations. The patients’ clinical and demographic
data are shown in Table 1. The controls were selected among
blood donors. Written informed consent to the study was
obtained from all the PD patients and control subjects. The
study was approved by the local ethics committee of Sapienza
University of Rome.
Genetic Analyses
DNA from peripheral blood was isolated using standard
procedures. MAPT haplotype was determined by testing for
the presence of a 238 bp deletion between exons 9 and 10
(del-In9), which is characteristic of the H2 haplotype. The
del-In9 polymorphism was amplified by polymerase chain
reaction (PCR) and separated on 6% native polyacrylamide gel
and then visualized after ethidium bromide staining by UV
transillumination. The amplification reaction was set to a volume
of 25 µl containing 1.5 mM MgCl2, 200 µM dNTP, 50 mM
KCl, 10 mM Tris-HCl, pH 8.3, 0.25 µM of each primer and
1 U of Promega Taq DNA polymerase, 30 amplification cycles
were performed. PCR conditions for del-In9 were: 94◦C for
30 s, 63◦C for 30 s and 72◦C for 30 s The forward primer was
5′-GTTTCCACTGTTTCCAGAGTTCC and the reverse primer
TABLE 1 | Demographic and clinical characteristics of patients and
controls.
Characteristic Controls PD NTD-PD TD-PD
N = 197 N = 181 N = 135 N = 46
Male sex, No. (%) 67% (132) 56% (102) 58% (78) 52% (24)
Age (Mean ± SD) 68.2 ± 18.8 71.8 ± 8.6 71.7 ± 8.5 71.9 ± 9.2
Age at onset (Mean ± SD) NA 60.5 ± 8.9 60.4 ± 9.2 61.0 ± 7.8
Disease duration (Mean ± SD) NA 10.4 ± 4.8 10.4 ± 5.1 10.3 ± 4.1
UPDRS III score NA 19.5 ± 9.6 20.6 ± 9.9 16.5 ± 8.1
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was 5′-TTTTACAATCTCAGCCCCTAGC. H1 yields a 574 bp
product and H2 a 336 bp product under these conditions.
The SNPs rs1467967, rs242557, rs3785883, rs2471738, rs7521
were detected by means of the restriction fragment length
polymorphism PCR (PCR-RFLP) method. To amplify by PCR
the MAPT haplotype SNPs of interest, oligonucleotide primer
pairs were designed using Primer3 software2. A volume of 10
µl of PCR product for each SNPs was digested by 1 U of
the corresponding restriction endonuclease: rs1467967 (DraI);
rs242557 (ApaHI); rs3785883 (BsaHI); rs2471738 (BstEII);
rs7521 (PstI). All nucleases were from New England Biolabs
and the reaction volume of 20 µl was incubated for 2 h at the
temperature indicated by the manufacturer. The sequences of
primers for PCR reactions, restriction enzymes used for RFLPs
and size of fragments are shown in Table 2. For the SNPs
rs1467967, rs242557 and rs2471738 a multiplex PCR reaction
was performed in a volume of 50 µl, at the following settings:
94◦C for 30 s, 60◦C for 30 s and 72◦C for 30 s. PCR conditions for
the rs3785883 were: 94◦C for 30 s, 54◦C for 30 s and 72◦C for 30
s. The SNP rs7521 was amplified using the following parameters:
94◦C for 30 s, 62◦C for 30 s and 72◦C for 30 s. Genotyping
accuracy was confirmed randomly by DNA sequencing.
Statistical Analysis
We assessed each SNP for Hardy-Weinberg equilibrium in cases
and control subjects. For all markers, Fisher’s exact test was
used to test for allele frequencies association between cases (PD,
NTD-PD, and TD-PD) and controls. P-values were considered
significant at P < 0.05.
The program FAMHAP Ver.193 (Herold and Becker, 2009)
was used to reconstruct H1 subhaplotypes and calculate
haplotypes frequencies. For comparison reasons, subhaplotypes
with frequencies <5% were included in the analysis only if
observed at a higher frequency (>5%) in one of the other groups.
We first performed a global likelihood ratio test to assess whether
the overall subhaplotype frequency distribution differed between
cases and control subjects. In instances in which the overall
2http://sourceforge.net/projects/primer3/
3http://famhap.meb.uni-bonn.de/
TABLE 2 | Primer sequences and restriction enzymes used for detection
of the investigated polymorphisms.
Gene polymorphism PCR primers Enzyme
(alleles) (5′−3′) (fragment bp)
rs1467967 (G/A) Fwr: CACAGCCACCCTCCCTCTAAC DraI
Rev: GGCTCCACCCTTCAGTTTTGGA (267/ 186, 81)
rs242557 (A/G) Fwr: CTTGATGATGCATGGACCTCTC ApaHI
Rev: TTGACAGTACCCACGACACGTG (211/ 139, 72)
rs3785883 (A/G) Fwr: CCATCACCTTGTCAGAAACTC BsaHI
Rev: AGCCATGTGGTAGCCTCAG (277/ 164, 113)
rs2471738 (T/C) Fwr: CTCTCTGGACCCTCATCCACC BstEII
Rev: GAGAACCGAATGAGGACTGGAA (170/ 104, 66)
rs7521 (G/A) Fwr: ACCTCTGTGCCACCTCTCAC PstI
Rev: AGGTGAGGCTCTAGGCCAGT (231/ 160, 71)
Fwr, forward primer; Rev, reverse primer.
distribution significantly differed we examined the effect of each
individual subhaplotype compared with all others. We calculated
pairwise LD (measured as D′) between subhaplotypes in cases
and control subjects, and created a graphic representations of
the data using Haploview 4.14 (Barrett et al., 2005). A Bonferroni
correction was used to take into account multiple testing.
RESULTS
Following the classification procedure, we found 46 TD-PD
and 135 NTD-PD patients. Patient groups (NTD-PD vs. TD-
PD) were comparable with regard to age, age at onset and
disease duration. A statistically significant difference in motor
performance assessed with UPDRS part III at last visit was
observed between the two PD groups (NTD-PD 20.6 ± 9.9 vs.
TD-PD 16.5± 8.1; p< 0.05; Table 1).
Six MAPT htSNPs were tested for association in all patients
and control group. Allele frequencies for all SNPs were in
Hardy-Weinberg equilibrium, except for rs2471738, for which
a marginally significant deviation was seen in cases (p = 0.02)
but not in control subjects (p = 0.9). To test the relation
between H1-SNPs and PD risk, we first performed a single-
locus analysis of the MAPT genetic variants. Results are shown
in Table 3. A significant overrepresentation of the H1 allele in
the entire PD group (comprising both NTD-PD and TD-PD)
compared with controls (79.5 vs. 69.5%; χ2 = 9.9; OR, 1.7;
95% CI, 1.2–2.4; p = 0.002) was detected. The association
was greater in the PD subgroup of NTD patients compared
with controls (82 vs. 69.5%; χ2 = 13.6; OR, 2.03; 95% CI,
1.4–3; p = 0.0003) and remained significant after correction for
multiple testing (pcorrect = 0.008), while no statistically significant
difference was disclosed between PD subgroup of TD patients
and control subjects (72 vs. 69.5%; χ2 = 0.17; OR, 1.1; 95% CI,
0.7–1.9; p = 0.7). Among the other SNPs, only the rs3785883
was marginally statistical significant in the NTD-PD subgroup
compared with control subjects (χ2 = 4.3; OR, 1.5; 95% CI,
1.02–2.3; p = 0.044), but this difference did not remain significant
after statistical correction considering the number of SNPs
analyzed.
To clarify the association found between PD and the
MAPT H1 variation and to assess whether any of the H1
subclades previously described (Myers et al., 2005; Pittman
et al., 2005) could be influencing PD risk or motor phenotypes,
we performed a haplotype association study comparing MAPT
subhaplotype frequencies between the different group of patients
and controls. On the H1 background, 20 subhaplotypes were
identified with a frequency of ≥1% and only those with
frequencies >5% in at least one of the groups in study were
considered for the analysis. A total of seven subhaplotypes
were selected (Table 4). Significant overall differences in
selected subhaplotype frequencies (defined by the tagging SNPs
rs1467967, rs242557, rs3785883, rs2471738, del-in9, rs7521)
were found between PD patients and controls (p = 0.014),
between NTD-PD and controls (p = 0.0005) and between
4https://www.broadinstitute.org/scientific-community/science/programs
/medical-and-population-genetics/haploview/downloads
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TABLE 3 | Microtubule-associated protein tau (MAPT) single single nucleotide polymorphisms (SNPs) association results.
Major allele frequency
Variant Location Major CO PD (p-value) OR NTD-PD (p-value) TD-PD (p-value)
in MAPT allele (95%CI) OR (95%CI) OR (95%CI)
rs1467967 5′Exon 1 A 59 60 (0.88) 63 (0.37) 51 (0.16)
1.02 (0.7–1.3) 1.16 (0.8–1.6) 0.7 (0.41–1.1)
rs242557 5′Exon 1 G 68 66 (0.53) 63 (0.2) 74 (0.31)
0.9 (0.67–1.2) 0.8 (0.58–1.1) 1.3 (0.8–1.2)
rs3785883 Intron 3 G 83.5 78 (0.064) 77 (0.044) 81.5 (0.64)
0.7 (0.5–1.02) 0.6 (0.45–0.98) 0.87 (0.5–1.6)
rs2471738 Intron 9 C 80 77 (0.4) 76 (0.25) 81.5 (0.77)
0.87 (0.6–1.2) 0.8 (0.5–1.2) 1.12 (0.6–2)
del-in9 Intron 9 H1 69.5 79.5 (0.002) 82 (0.0003) 72 (0.7)
1.7 (1.2–2.4) 2.03 (1.4–3) 1.1 (0.7–1.8)
rs7521 3′Exon 14 G 55 53 (0.6) 52 (0.47) 55 (1)
0.92 (0.7–1.2) 0.89 (0.6–1.2) 1.03 (0.6–1.6)
Abbreviations: CO, controls; PD, Parkinson Disease; PD-NTD, Parkinson Disease Non Tremor Dominant; PD-TD, Parkinson Disease Tremor Dominant; OR, odds ratio;
95% CI, Confidence Interval. Boldface values indicate significant results after Bonferroni correction for multiple testing (pcorrect = 0.008).
TABLE 4 | MAPT haplotype association results.
Haplotype frequencyHaplotype
Haplotype ID variantsa CO PD NTD-PD TD-PD
H2a AGGCdelG 21 16.7 13b 26c
H1b GGGCinsA 17 17 16 24
H1c AAGTinsG 7 8.8 10.5 5
H1d AAGCinsA 3 5.3 5.6 5.3
H1e AGGCinsA 6.3 8.2 9.3 3.7
H1h AGACinsA 2.6 6.7d 7.4e 5.3
H1i GAGCinsA 8 5 4.6 5.3
0.015 0.0005 0.35 (0.035)
Abbreviations: CO, controls; PD, Parkinson Disease; PD-NTD, Parkinson Disease
Non Tremor Dominant; PD-TD, Parkinson Disease Tremor Dominant; MAPT,
microtubule-associated protein tau; OR, odds ratio; 95% CI, Confidence Interval.
aAlleles for the SNPs defining the haplotype are given in the 5′ to 3′ order as follows:
rs1467967, rs242557, rs3785883, rs2471738, del-In9, and rs7521. b0.024, OR
0.6; 95%CI 0.4–0.9: NTD-PD vs. CO. c0.018, OR 0.5; 95%CI 0.28–0.87: NTD-PD
vs. TD-PD. d0.013, OR 2.6; 95%CI 1.2–5.5: PD vs. CO. e0.007, OR 2.9; 95%CI
1.3-6.3; NTD-PD vs.CO. (Boldface value indicate significant result after
Bonferroni correction for multiple testing, pcorrect = 0.00714). Numbers on the
last line indicate p values that result from global haplotype frequency comparison
between each group of patients and controls, while the p value in brackets results
from comparison between TD-PD and NTD-PD patients.
TD-PD vs. NTD-PD (p = 0.035), while no statistically significant
difference was detected between controls and TD-PD patients
(p = 0.35).
The MAPT H2a haplotype was significantly underrepresented
in the NTD-PD subgroup compared with controls (p = 0.024;
OR, 0.6) and with TD-PD patients (p = 0.018; OR, 0.5).
Detailed analyses showed a significant difference in the
frequency of the H1h subhaplotype in the PD group (p = 0.013;
OR, 2.6) compared with controls. However, the difference was
greater in the subgroup of NTD-PD patients (p = 0.007; OR, 2.9).
After correction for the number of haplotypes analyzed only this
last difference remained statistically significant.
The pairwise linkage disequilibrium analysis (LD) for all
SNPs was performed in the control and PD groups. The LD
plot showed in the Figure 1, indicates in PD patients, that
alleles at rs242557, rs3785883, rs2471738 and rs7521 are in
strong LD with the del-in9 (marker 5), but are not in strong
linkage with each others, indicating that these markers are H1
specific.
FIGURE 1 | Linkage disequilibrium (LD) between the microtubule-
associated protein tau (MAPT) H1 genotyped single nucleotide
polymorphisms (SNPs) in our PD group. The relative position of the MAPT
H1 tagging SNPs, is shown (top). Within each diamond the pairwise
standardized coefficient of LD (D′ values × 100) are presented.
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DISCUSSION
Analyzing the role of MAPT locus in neurodegenerative
disorders, such as PD, represents an effort to elucidate the
interaction between genetics and functional disease outcomes.
Although several studies including ours have found an
association between the H1 haplotype and PD, the functional role
of this variant still remains to be identified.
This article aimed at refining the MAPT role in PD by
examining the architecture of the entire gene in order to
determine its possible associations with PD, and PD motor
phenotypes, in a cohort of patients of Italian ancestry. Our
results are consistent with the growing body of evidence that
supports the MAPT H1 haplotype as a risk factor for sporadic
PD. Moreover, we observed a peculiar risk distribution of
MAPT haplotype, and H1 subhaplotype, according to PD
motor phenotype. Indeed, while NTD-PD subgroup showed
a statistically significant overrepresentation of H1 clade, no
differences were observed between TD-PD subgroup and control
subjects. Among the other SNPs analyzed, the rs3785883
polymorphism was nominally significant, exclusively in the
NTD-PD subgroup compared with controls. This finding is
consistent with a previous study where a moderate association
at SNP rs3785883 was also found in a Greek cohort of
PD patients (Fung et al., 2006). With regard to MAPT
subhaplotype, we found that H1h was associated with PD and
this association remained statistically significant after correction
for multiple testing when NTD-PD subgroup was considered.
To our knowledge this is the first study comprehensively
assessing MAPT locus in PD according to clinical motor
subtype and the strong point of this study is the regular
motor clinical assessment for all patients included in the
cohort.
The results of our study potentially raise two orders of
consideration: the first report of a significant PD risk of the H1
haplotype in a PD subgroup, namely NTD-PD and the original
finding of an association between the H1h subhaplotype and the
same PD clinical subtype, in a cohort of Caucasian European
ancestry.
At present, phenotype-genotype association studies that
analyze the role of MAPT haplotypes on PD are mostly focused
on cognitive profiling. These researches overall indicate an
involvement of H1 haplotype on specific cognitive domains such
as memory and visuo-spatial functions (Williams-Gray et al.,
2009). According to these studies, MAPT variation influences
cognition and the function of specific brain circuitry even in
early phases of PD (Nombela et al., 2014) and even in healthy
control subjects (Winder-Rhodes et al., 2015). Although the
relationship between MAPT haplotype and cognitive functions
remains to be determined since no specific regional degeneration
or neurochemical alterations have been provided, the effect
seems to be detectable even in relative small number of
subjects.
Unlike many other quantitative phenotypic traits, there are
now evidences suggesting that clinical motor phenotype of
PD may not represent a mere semiological matter. Indeed,
while the TD-PD patients could be considered a subgroup
with a benign clinical course and a slower process of
degeneration at least for the most part of the disease
course (Selikhova et al., 2009, 2013; Eggers et al., 2012;
Deuschl, 2013), NTD-PD are likely more prone to develop a
series of motor and non motor complaints, inherent to the
spreading of the degenerative process (Rosenberg-Katz et al.,
2013; Zhang et al., 2013; Herman et al., 2014; Solla et al.,
2015).
Interestingly, the contribution of MAPT gene in motor
impairment has been described in a large community-
based cohort of neurologically healthy aging individuals
(Shulman et al., 2014), where an association between
H1 haplotype and mild parkinsonian signs, especially
bradykinesia, has been observed without evidence of PD
hallmark at pathological assessment. The authors speculated
that neuroanatomical dysfunction of cortico-nigro-striatal
pathways, different from those classically observed in PD,
may contribute to the development of parkinsonian signs.
Therefore, given the prevailing view of H1 haplotype as a
genetic risk factor for neurodegeneration, we can speculate
that H1 background may partake to the expression of a PD
clinical motor subtype associated with increased functional
disability.
On the other hand, given the overall underrepresentation
of H2 haplotype in a range of neurodegenerative disorders
and assuming that this haplotype is associated with more
efficient brain function, our observation of a significant
overrepresentation of H2 in TD-PD may indicate a protective
role of the H2 haplotype. Some studies assessed the role of MAPT
variants in gene expression (Hutton et al., 1998; Spillantini
et al., 1998; Caffrey et al., 2006; Pittman et al., 2006). Some
authors reported that the disease risk conferred by MAPT
variants could be related to a higher total or 4R tau levels.
Additionally, a protective effect of MAPT H2-haplotype due to
an increase espression in N-terminal exon-containing MAPT
transcripts has been speculated. Indeed, recent work suggested
that N-terminal transcripts may play a role in the regulation
of tau solubility, inhibiting tau polymerization (Horowitz et al.,
2006).
Nevertheless, although several lines of evidence, including
basic researches, pathological findings and genotype-phenotype
association support the role of MAPT haplotypes in PD, the
mechanistic model of this link remains to be determined.
Moreover, the pathological findings related to MAPT
background in neurodegenerative disorders are partially
conflicting. Indeed, while some studies conducted on PSP
human brain indicate that H1 haplotype does not affect the
pathological or biochemical phenotypes (Liu et al., 2001),
others found an higher expression of 4R-tau from the H1
haplotype compared to H2. Other authors observed that
the MAPT H1 haplotype enhances the overall α-synuclein
deposition type pathology in dementia with Lewy Body (Colom-
Cadena et al., 2013) and Alzheimer’s disease (Wider et al.,
2012).
However, no comprehensive assessments of α-synuclein
burden or Alzheimer-like pathology according to MAPT
haplotype are currently available in PD; therefore, systematic
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and well-powered analysis exploring the functional outcomes
of MAPT region variations remain mandatory. Furthermore,
we found that a specific subhaplotype, the H1h variant, was
overrepresented in our PD population, more significantly in
NTD-PD patients.
A number of studies have been performed for association of
MAPT subhaplotypes variability and PD with inconsistent results
(Fung et al., 2006; Vandrovcova et al., 2009; Seto-Salvia et al.,
2011). Moreover, other studies analyzed just few of the SNPs
described to characterize the H1 specific subhaplotypes (Fidani
et al., 2006; Winkler et al., 2007; Das et al., 2009; Refenes et al.,
2009; Huang et al., 2015; Wang et al., 2016).
Given the concern that H1h variants may be driven by
the genetic architecture related to ethnicity (Fung et al.,
2006), it is worth considering that a biological link between
such variant and neurodegenerative process has been
formerly reported. Indeed, it has been found in AD that
the A-allele of the rs3785883 SNP is associated with increased
cerebrospinal fluid (CSF) tau levels and tau mRNA expression
(Kauwe et al., 2008). Moreover, the authors observed that
the MAPT genetic variation defined as H1h subhaplotype
showed significant elevation of CSF tau compared with
the H2 haplotype. The contribution of the A-allele of the
rs3785883 to tau expressions in AD has been subsequently
confirmed in a larger series (Allen et al., 2014). Therefore,
our findings may be congruent with, and complementary
to these reports considering that NTD-PD patients showed
significantly higher levels of CSF tau protein and tau/beta index
if compared to TD-PD (Jellinger, 2012; Prˇikrylová Vranová et al.,
2012).
If confirmed, this result may indicate that a specific H1
subhaplotype increases the risk of developing a NTD-PD disease,
at least in populations of South European ancestry. Our study
supports the hypothesis that genetic variability in the MAPT
region is involved in PD susceptibility and may contribute to PD
phenotypic expression, confirming that large-scale evaluation in
different populations could be relevant to understand the role of
population-specific heterogeneity.
The main limitation of this study is the relative small sample
size; due to this major issue the results should be interpreted
with caution until further studies in larger series of patient will
ascertain the significance of specific subhaplotypes in PD clinical
traits.
Given the findings that H1 may act synergistically with other
gene variants in determining risk for PD, future researches
should concern with gene–gene interactions to provide critical
insights into mechanisms of disease susceptibility.
Nevertheless, the genetic architecture of MAPT in
determining PD phenotypic expression as well as the possible
functional effect of H1h subhaplotype deserves attention and
replication in larger series.
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